Abstracts tagged "outcome measures and scleroderma"

Abstract Number: 1420 • 2018 ACR/ARHP Annual Meeting
Prospective Validation of Cone Beam Computed Tomography for the Assessment of Disease Progression in Linear Scleroderma of the Face
Alessandra Meneghel¹, Stefano Puggina², Eleni Kamburi³, Giorgia Martini³, Fabio Vittadello³ and Francesco Zulian¹, ¹University of Padua, Department of Woman and Child Health, Padua, Italy, ²Unix Radiology Service, Affidea Group, Piove di Sacco, Italy, ³Department of Woman and Child Health, University of Padua, Padua, Italy
Background/Purpose: Currently, the techniques used for the monitoring of Localized Scleroderma of the face (LSF) have significant limitations. We prospectively evaluated the reliability of the…
Abstract Number: 1716 • 2018 ACR/ARHP Annual Meeting
Evaluation of American College of Rheumatology Provisional Composite Response Index in Systemic Sclerosis in a Phase II Trial of Abatacept Vs. Placebo
Dinesh Khanna¹ and Cathie Spino², ¹Division of Rheumatology, Department of Internal Medicine, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI, ²Biostatistics, University of Michigan, Ann Arbor, MI
Background/Purpose: Treatment with CTLA4Ig, abatacept (ABA), in early diffuse cutaneous systemic sclerosis (dcSSc; the Phase 2 ASSETtrial) showed evidence of improvements in modified Rodnan skin…
Abstract Number: 1287 • 2017 ACR/ARHP Annual Meeting
Cone Beam Computed Tomography for the Assessment of Linear Scleroderma of the Face
Francesco Zulian¹, Chiara Di Giovanni², Stafano Puggina³, Alessandra Meneghel¹, Sabina Trainito⁴ and Giorgia Martini², ¹University of Padua, Department of Woman and Child Health, Padua, Italy, ²Department of Woman and Child Health, University of Padua, Padua, Italy, ³Unix Radiology Service, Affidea Group inc., Piove di Sacco, Italy, ⁴Division of Physical Medicine and Rehabilitation, University of Padua, Padua, Italy
Background/Purpose: Linear scleroderma of the face (LSF) is a very disabling condition and, to date, standardized and validated methods for assessing and monitoring the disease…
Abstract Number: 1686 • 2017 ACR/ARHP Annual Meeting
Topical Nitroglycerine (NTG) Vs Matching Vehicle in Secondary Raynaud Phenomenon (RP) – a Double-Blind Crossover Study of Subjective and Physiologic Responses to Controlled Cold Challenge
Dinesh Khanna¹, Lorele Mendez², Rajaie Namas³, Mary Ellen Csuka⁴, Paul Caldron⁵, Jerry A. Molitor⁶, Alan J. Kivitz⁷, Philip Waller⁸, Lee Shapiro⁹, Sabeen Najam¹⁰, Amber Khan¹¹, Virginia D. Steen¹², Aneureka Chadha¹³ and James R Seibold¹⁴, ¹University of Michigan, Ann Arbor, MI, ²Medical Research Center of Miami, Miami, FL, ³Department of Medicine [Division of Rheumatology], University of Michigan, Ann Arbor, MI, ⁴Medicine, Medical College of Wisconsin, Milwaukee, WI, ⁵Arizona Arthritis & Rheumatology Research PLLC, Phoenix, AZ, ⁶Rheumatic & Autoimmune Diseases, University of Minnesota, Minneapolis, MN, ⁷Altoona Center for Clinical Research, Duncansville, PA, ⁸Accurate Clinical Research Inc, Houston, TX, ⁹Rheumatology, Albany Medical College, Albany, NY, ¹⁰Accurate Clinical Management LLC, Baytown, TX, ¹¹Accurate Clinical Management LLC, Houston, TX, ¹²Division of Rheumatology, Department of Medicine, MedStar Georgetown University Hospital, Washington, DC, ¹³Austin Regional Clinic, Austin, TX, ¹⁴Scleroderma Research Consultants LLC, Litchfield, CT
Background/Purpose: A topical therapy for either prevention or palliation of attacks would offer unique advantages to selected patients with Raynaud phenomenon (RP). This study used…
Abstract Number: 830 • 2016 ACR/ARHP Annual Meeting
Cardiopulmonary Disease Development in Anti-RNA Polymerase III Positive Systemic Sclerosis; Comparative Analyses from an Unselected, Prospective Patient Cohort
Anna Hoffmann-Vold¹, Anders Heiervang Tennøe², Oyvind Midtvedt², May Brit Lund³, Torhild Garen², Fadi El-Hage⁴, Trond Mogens Aalokken⁵, Eli Taraldsrud⁴ and Øyvind Molberg², ¹Division of Rheumatology, Oslo University Hospital, Oslo, Norway, ²Rheumatology, Oslo University Hospital, Oslo, Norway, ³Respiratory Medicine, Oslo University Hospital, Oslo, Norway, ⁴Oslo University Hospital, Oslo, Norway, ⁵Radiology, Oslo University Hospital, Oslo, Norway
Background/Purpose: Extensive skin disease and renal crisis are hallmarks of anti-RNA polymerase III (RNAP) positive systemic sclerosis (SSc), while data on lung and heart involvement…
Abstract Number: 2981 • 2015 ACR/ARHP Annual Meeting
Measurement of Tissue Damage in Scleroderma Using Digital Mammographic Xrays: A Proof of Concept Study
John Highton¹, Terence Doyle² and Simon Stebbings³, ¹Dept of Medicine, University of Otago, Dunedin, New Zealand, ²Medicine, University of Otago, Dunedin, New Zealand, ³Dunedin School of Medicine, University of Otago, Dunedin, New Zealand
Background/Purpose: We have used digital mammographic soft tissue Xrays of the fingers from patients with Scleroderma and related conditons to show damage related to the…
Abstract Number: 2715 • 2014 ACR/ARHP Annual Meeting
Reliability and Validity of the Duruöz Hand Index in an Argentinian Population with Scleroderma
Vanesa Duarte¹, Gloria Crespo¹, Maritza Manzano¹, María Victoria Martire², Santiago Scarafia¹, Lucila Marino³, Felix Romanini¹, Marta Mamani¹ and Anastasia Secco¹, ¹Rheumatology, Hospital Bernardino Rivadavia, Buenos Aires, Argentina, ²Reumatología, Hospital Bernardino Rivadavia, Buenos Aires, Argentina, ³Rheumathology, Hospital Bernardino Rivadavia, Buenos Aires, Argentina
Background/Purpose: The Duruöz Hand Index (DIH) is a reliable tool for the evaluation of hand´s function in patients with scleroderma. The aim of our study…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].